Ribo-regulators that sense trace antibiotics

Project Information

DrugSense

Grant agreement ID: 704340

DOI

10.3030/704340

Project closed

EC signature date 21 April 2016

Start date 1 May 2016

End date 30 April 2017

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 150 000,00

EU contribution

€ 150 000,00

Coordinated by

WEIZMANN INSTITUTE OF SCIENCE
Israel

Periodic Reporting for period 1 - DrugSense (Ribo-regulators that sense trace antibiotics)

Reporting period: 2016-05-01 to 2017-04-30

Summary of the context and overall objectives of the project

The DrugSense project was aimed at commercializing the technology developed at the Sorek lab at the Weizmann Institute of Science, covered under U.S. provisional patent application 62/200,662. As planned, the expenses were used to cover the commercialization efforts as well as proof of concept experiments. These efforts resulted in the commercialization of the technology, which was eventually licensed by BiomX, a company developing novel therapeutics to alleviate microbiome-related diseases.


There is no overlap between the time that the PI dedicate to this project- DraugSense and the time that the PI dedicate to project PROKRNA.